Company / Operating Income per Share
UroGen Pharma Ltd. Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$2.96
FY2025
5-year range
-$4.16 / -$2.02
FY2021-FY2025
Trend
-46.6%
vs FY2024
Sector context
#138 of 201
Health Care
What the data says
At $-2.96, UroGen Pharma Ltd.'s operating income per share ranks #138 of 201 in the Health Care sector. Operating Income per Share has fluctuated over the past 10 years, ranging from $-5.61 in FY2018 to $0.35 in FY2016.
Based on SEC 10-K filings.
-2.96 in FY2025.
Improved from $-3.42 to $-2.96 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#138 of 201 in Health CareTop 69% of 201This company -$2.96 Sector average -$28.56
▼
+89.6% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 46.6% year-over-year.
- Ranks #138 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2016.
- Lowest operating income per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.96 | -46.6% |
| FY2024 | -$2.02 | +41.0% |
| FY2023 | -$3.42 | +16.8% |
| FY2022 | -$4.11 | +1.3% |
| FY2021 | -$4.16 | +20.0% |
| FY2020 | -$5.21 | -323.2% |
| FY2019 | -$1.23 | +78.1% |
| FY2018 | -$5.61 | -173.4% |
| FY2017 | -$2.05 | -693.2% |
| FY2016 | $0.35 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026